The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis-Reference-Cited by-同舟云学术

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

Published:2008-10-16 Issue:11 Volume:24 Page:3223-3237
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Lanctôt Krista L.,Masoud Shababa T.,Paes Bosco A.,Tarride Jean-Eric,Chiu Aaron,Hui Charles,Francis Philip L.,Oh Paul I.

Publisher

Informa Healthcare

Subject

General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1185/03007990802484234

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants;Vaccine;2024-08

2. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants;2024-03-24

3. Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants;Frontiers in Pediatrics;2024-01-12

4. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study;The Lancet Regional Health - Americas;2023-12

5. Cost-Effectiveness Analysis of Nirsevimab and RSVpreF Vaccine Prevention Strategies for Respiratory Syncytial Virus Disease in infants: A Canadian Immunisation Research Network (CIRN) Study;2023-07-16